Vident Advisory
ARCT icon

Vident Advisory’s Arcturus Therapeutics ARCT Stock Holding History

Vident Advisory’s Portfolio ARCT Stock Details ARCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-8,039
Closed -$205K – 1316
2023
Q3 		$205K Buy
+8,039
New +$248K 0.01% 1102

Other funds holding ARCT

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ARK Investment Management
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $175B AUM 40.63% 1-Year Est. Return
Nikko Asset Management Americas
Nikko Asset Management Americas New York $7.75B AUM 33.73% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Woodline Partners
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vident Advisory's ARCT Position: Q4 2023 in Review

Vident Advisory sold out of Arcturus Therapeutics (ARCT) in Q4 2023, closing a stake of 8,039 shares — an estimated $205K sold.

Vident Advisory first reported a position in ARCT in Q3 2023 and held it in 1 quarter. The position peaked at $205K in Q3 2023. 165 funds tracked by Wall St. Rank hold ARCT as of Q4 2023.

  • Vident Advisory reported no remaining Arcturus Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Vident Advisory sold 8,039 Arcturus Therapeutics shares in Q4 2023, an estimated $205K.
  • Vident Advisory first reported a position in Arcturus Therapeutics in Q3 2023 and held it in 1 quarter.
  • Vident Advisory's Arcturus Therapeutics position peaked at $205K in Q3 2023.
  • 165 funds tracked by Wall St. Rank held Arcturus Therapeutics as of Q4 2023.

Based on Vident Advisory's 13F filing for Q4 2023, filed 14 Feb 2024.